Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.

A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same…

Earlier this month, the FDA banned all products being shipped to the U.S. by a Chinese API maker, and a new warning letter explains why. It appears the…

India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.…

A U.S. generics manufacturing site that India’s Lupin picked up in its 2015 buyout of GAVIS Pharmaceuticals has now been significantly expanded as the…

Takeda’s plan to launch a Hib vaccine in Japan has ended in smoke as GlaxoSmithKline has terminated production of Vaxem Hib.

The FDA has warned Vikshara Trading & Investments for its repeated efforts to keep inspectors from getting a look into its filthy plant.

The FDA has cited an Aurobindo sterile manufacturing plant in India for not doing everything it can to prevent contamination, according to a new report.

Manufacturing